Dose Escalation for Prostate Cancer Using the Three-Dimensional Conformal Dynamic Arc Technique: Analysis of 542 Consecutive Patients

International Journal of Radiation Oncology Biology Physics

Volumn 71, Issue 3, 2008, Pages 784-794

  Jereczek Fossa, Barbara A ^a,b   Vavassori, Andrea ^a   Fodor, Cristiana ^a   Santoro, Luigi ^a   Zerini, Dario ^a   Cattani, Federica ^a   Garibaldi, Cristina ^a   Cambria, Raffaella ^a   Fodor, Andrei ^a   Boboc, Genoveva Ionela ^a   Vitolo, Viviana ^a   Ivaldi, Giovanni Battista ^a   Musi, Gennaro ^a   de Cobelli, Ottavio ^a,b   Orecchia, Roberto ^a,b  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Conformal radiotherapy; Dose escalation; Dynamic arc; Prostate cancer

Indexed keywords

DOSIMETRY; ONCOLOGY; TOXICITY; TUMORS;

CONFORMAL RADIOTHERAPY; DOSE ESCALATION; DYNAMIC ARC; MULTIVARIATE ANALYSIS;

RADIOTHERAPY;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOSIMETRY; FEASIBILITY STUDY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RADIATION DOSE DISTRIBUTION; RADIATION DOSE FRACTIONATION; RADIATION RESPONSE; RECTUM INJURY; SURVIVAL RATE; THREE DIMENSIONAL CONFORMAL DYNAMIC ARC RADIOTHERAPY; TRANSURETHRAL RESECTION; URINARY TRACT INJURY;

AGED; AGED, 80 AND OVER; COMORBIDITY; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; MALE; MIDDLE AGED; PREVALENCE; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 44449122328     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.10.041     Document Type: Article

References (56)

1. Kupelian P.A., Buchsbaum J.C., Eishaikh M.A., et al. Improvement in relapse-free survival throughout the PSA era in patients with localized prostate cancer treated with definitive radiotherapy: Year of treatment an independent predictor of outcome. Int J Radiat Oncol Biol Phys 57 (2003) 629-634
2. Peeters S.T.H., Heemsbergen W.D., Koper P.C.M., et al. Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 24 (2006) 1990-1996
3. Pollack A., Zagars G.K., Starkschall G., et al. Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53 (2002) 1097-1105
4. Jereczek-Fossa B.A., and Orecchia R. Evidence-based radiation oncology: Definitive, adjuvant and salvage radiotherapy for non-metastatic prostate cancer. Radiother Oncol 84 (2007) 197-215
5. Dearnaley D.P., Hall E., Lawrence D., et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. Br J Cancer 92 (2005) 488-498
6. Dearnaley D.P., Sydes M.R., Graham J.D., et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First results from the MRC RT01 randomised controlled trial. Lancet Oncol 8 (2007) 475-487
7. van Tol-Geerdink J.J., Stalmeier P.F., Pasker-De Jong P.C.M., et al. Systematic review of the effect of radiation dose on tumor control and morbidity in the treatment of prostate cancer by 3D-CRT. Int J Radiat Oncol Biol Phys 64 (2006) 534-543
8. Zietman A.L., DeSilvio M.L., Slater J.D., et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial. JAMA 294 (2005) 1233-1239
9. Boersma L.J., van den Brink M., Bruce A.M., et al. Estimation of the incidence of late bladder and rectum complications after high-dose (70-78 Gy) conformal radiotherapy prostate cancer. Int J Radiat Oncol Biol Phys 41 (1998) 83-92
10. Fiorino C., Sanguineti G., Cozzarini C., et al. Rectal dose-volume constraints in high-dose radiotherapy of localized prostate cancer. Int J Radiat Oncol Biol Phys 57 (2003) 953-962
11. Greco C., Mazzetta C., Cattani F., et al. Finding dose-volume constraints to reduce late rectal toxicity following 3D-conformal radiotherapy (3D-CRT) of prostate cancer. Radiother Oncol 69 (2003) 215-222
12. Koper P.C.M., Heemsbergen W.D., Hoogeman M.S., et al. Impact of volume and location of irradiated rectum wall on rectal blood loss after radiotherapy of prostate cancer. Int J Radiat Oncol Biol Phys 58 (2004) 1072-1082
13. Nuyttens J.J., Milito S., Rust P.F., et al. Dose-volume relationship for acute side effects during high dose conformal radiotherapy for prostate cancer. Radiother Oncol 64 (2002) 209-214
14. Peeters S.T.H., Hoogeman M.S., Heemsbergen W.D., et al. Volume and hormonal effects for acute side effects of rectum and bladder during conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 63 (2005) 1142-1152
15. Vavassori V., Fiorino C., Rancati T., et al. Predictors for rectal and intestinal acute toxicities during prostate cancer high-dose 3D-CRT: Results of a prospective multicenter study. Int J Radiat Oncol Biol Phys (2007, January 22) [Epub ahead of print]
16. Bedford J.L., Khoo V.S., Oldham M., et al. A comparison of coplanar four-field techniques for conformal radiotherapy of the prostate. Radiother Oncol 51 (1999) 225-235
17. De Meerleer G., Villers G., Bral S., et al. The magnetic resonance detected intraprostatic lesion in prostate cancer: Planning and delivery of intensity-modulated radiotherapy. Radiother Oncol 75 (2005) 325-333
18. Kagan A.R., and Schulz R.J. Intensity-modulated radiotherapy for adenocarcinoma of the prostate: A point of view. Int J Radiat Oncol Biol Phys 62 (2005) 454-459
19. Zelefsky M.J., Fuks Z., Hunt M., et al. High-dose intensity modulated radiation therapy for prostate cancer: Early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 53 (2002) 1111-1116
20. Akazawa P.F., Roach III M., Pickett B., et al. Three dimensional comparison of blocked arcs vs. four and six field conformal treatment of the prostate. Radiother Oncol 41 (1996) 83-88
21. Francia A.E., Antognoni P., Bretoni F., et al. High conformal transcutaneous dynamic radiotherapy (RT) with microMLC in organ confined prostate cancer: Its advantages in comparison with conventional 3D-conformation techniques. [abstract]. Tumori 4 Suppl. (2005) S60-S61
22. Roach III M., Akazawa P.F., Pickett B., et al. Bilateral arcs using "averaged beam's eye view": A simplified technique for delivering 3-D based conformal radiotherapy. Med Dosim 19 (1994) 159-168
23. Tobler M., Watson G., and Laevitt D.D. The application of dynamic filed shaping and dynamic dose rate control in conformal rotational treatment of the prostate. Med Dosim 27 (2002) 251-254
24. Bauman G., Gete E., Chen J.Z., and Wong E. Simplified intensity-modulated arc therapy for dose escalated prostate cancer radiotherapy. Med Dosim 29 (2004) 18-25
25. Wong E., Chen J.Z., and Greenland J. Intensity-modulated arc therapy simplified. Int J Radiat Oncol Biol Phys 53 (2002) 222-235
26. King C.R., Lehmann J., Adler J.R., and Hai J. CyberKnife radiotherapy for localized prostate cancer: Rationale and technical feasibility. Technol Cancer Res Treat 2 (2003) 25-29
27. Ghilezan M., Ivaldi G., Cattani F., et al. 3D-conformal radiation therapy in prostate cancer. Technical considerations after 5 years of experience and 334 patients treated at the Instituto Europeo di Oncologia of Milan, Italy. Tumori 87 (2001) 317-323
28. Jereczek-Fossa B.A., Cattani F., D'Onofrio A., et al. Dose distribution in 3-dimensional conformal radiotherapy for prostate cancer: Comparison of two treatment techniques (six coplanar fields and two dynamic arcs). Radiother Oncol 81 (2006) 294-302
29. National Comprehensive Cancer Network (NCCN). Prostate cancer. National Comprehensive Cancer network Clinical Practice Guidelines in Oncology, version 1.2007 (March 2007), NCCN, Jenkinstown, PA. http://www.nccn.org/professionals/physician_gls/default.asp Accessed May 1, 2007
30. International Commission on Radiation Units and Measurements (ICRU). Report 62: Prescribing, recording and reporting photon beam therapy (supplement to ICRU report 50) (1999), International Commission on Radiation Units and Measurements, Bethesda, MD
31. Cox J.D., Stetz J., and Pajak T.F. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31 (1995) 1341-1346
32. Roach III M., Hanks G., and Thames Jr. T. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65 (2006) 965-974
33. American Society for Therapeutic Radiology and Oncology: Consensus statement: Guidelines for PSA following radiation therapy-American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys 37 (1997) 1035-1041
34. Kaplan E., and Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
35. Peto R., Pike M.C., Armitage P., et al. Design and analysis of randomized clinical trials requiring prolonged observation on each patient. II. Analysis and examples Br J Cancer 35 (1977) 1-39
36. Cox D.R. Regression models and life-tables (with discussion). J Royal Stat Society Series B 34 (1972) 187-220
37. Harrell F.E.J. Regression modelling strategies (2001), Springer-Verlag, New York
38. Marubini E., and Valsecchi M.G. Analysing survival data from clinical trials and observational studies (1995), Wiley, Chichester, England
39. Eade T.N., Hanlon A.L., Horwitz E.M., et al. What dose of external-beam radiation is high enough for prostate cancer?. Int J Radiat Oncol Biol Phys 68 (2007) 682-689
40. Vicini F.A., Abner A., Baglan K.L., et al. Defining a dose-response relationship with radiotherapy for prostate cancer: Is more really better?. Int J Radiat Oncol Biol Phys 51 (2001) 1200-1208
41. Lukka H., Hayter C., Julian J.A., et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol 23 (2005) 6132-6138
42. Thames H.D., Kuban D.A., DeSilvio M.L., et al. Increasing external beam dose for T1-T2 prostate cancer: Effect on risk groups. Int J Radiat Oncol Biol Phys 65 (2006) 975-981
43. Vora S.A., Wong W.W., Schild S.E., et al. Analysis of biochemical control and prognostic factors in patients treated with either low-dose three-dimensional conformal radiation therapy or high-dose intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 68 (2007) 1053-1058
44. Speight J.L., and Roach III M. Advances in the treatment of localized prostate cancer: The role of anatomic and functional imaging in men managed with radiotherapy. J Clin Oncol 25 (2007) 987-995
45. van Lin E.N., Futterer J.J., Heijmink S.W., et al. IMRT boost dose planning on dominant intraprostatic lesions: Gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI. Int J Radiat Oncol Biol Phys 65 (2006) 291-303
46. Xia P., Pickett B., Vigneault E., et al. Forward or inversely planned segmental multileaf collimator IMRT and sequential tomotherapy to treat multiple dominant intraprostatic lesions of prostate cancer to 90 Gy. Int J Radiat Oncol Biol Phys 51 (2001) 244-254
47. Sathya J.R., Davis I.R., Julian J.A., et al. Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol 23 (2005) 1192-1199
48. Shipley W.U., Verhey L.J., Munzenrider J.E., et al. Advanced prostate cancer: The results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. Int J Radiat Oncol Biol Phys 32 (1995) 3-12
49. Beckendorf V., Guerif S., Le Prise E., et al. The GETUG 70 Gy vs. 80 Gy randomized trial for localized prostate cancer: Feasibility and acute toxicity. Int J Radiat Oncol Biol Phys 60 (2004) 1056-1065
50. Hanks G.E., Hanlon A.L., Pinover W.H., et al. Dose selection for prostate cancer patients based on dose comparison and dose response studies. Int J Radiat Oncol Biol Phys 46 (2000) 823-832
51. Pollack A., Zagars G.K., Smith L.G., et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol 18 (2000) 3904-3911
52. Dearnaley D.P., Sydes M.R., Langley R.E., et al. The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: Results from the MRC RT01 trial (ISRCTN47772397). Radiother Oncol 83 (2007) 31-41
53. Denham J.W. MRC RT01: A important trial. Lancet Oncol 8 (2007) 459-460
54. Christie D.R.H., Denham J.W., Steigler A., et al. Delayed rectal and urinary symptomatology in patients treated for prostate cancer by radiotherapy with or without short term neo-adjuvant androgen deprivation. Radiother Oncol 77 (2005) 117-125
55. Morris D., Emami B., Mauch P.M., et al. Evidence-based review of three-dimensional conformal radiotherapy for localized prostate cancer: an ASTRO outcomes initiative. Int J Radiat Oncol Biol Phys 62 (2005) 3-19
56. Maartense S., Hermans J., and Leer J.W. Radiation therapy in localized prostate cancer: Long-term results and late toxicity. Clin Oncol R Coll Radiol 12 (2000) 222-228